Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
The solvency position, as indicated by the provided ratios, demonstrates a generally stable profile over the analyzed period, with some fluctuations. Overall, the company maintains a moderate level of debt relative to its equity, capital, and assets. However, recent quarters suggest a slight increase in leverage.
- Debt to Equity
- The debt to equity ratio generally decreased from 0.57 in July 2020 to a low of 0.44 in July 2022. A subsequent increase is observed, rising to 0.60 in January 2025, indicating a growing reliance on debt financing relative to equity. The ratio concludes the period at 0.57 in July 2025, showing a slight decrease from the peak but remaining elevated compared to earlier periods.
- Debt to Capital
- Similar to the debt to equity ratio, debt to capital exhibited a declining trend from 0.36 in July 2020 to 0.31 in April 2022. The ratio then increased to 0.37 in July 2024 and remained at that level through January 2025, before decreasing slightly to 0.36 in July 2025. This suggests a moderate increase in the proportion of debt used to finance the company’s operations and assets.
- Debt to Assets
- The debt to assets ratio followed a similar pattern, decreasing from 0.31 in July 2020 to 0.26 in July 2022. It then experienced an increase, reaching 0.31 in July 2024 and concluding the period at 0.31 in July 2025. This indicates a moderate increase in the proportion of assets financed by debt.
- Financial Leverage
- Financial leverage, as measured by the ratio, generally decreased from 1.87 in July 2020 to 1.71 in July 2022. The ratio then increased to 1.87 in July 2024, and finished the period at 1.87 in July 2025. This suggests a moderate increase in the company’s use of debt to amplify returns on equity.
- Interest Coverage
- The interest coverage ratio demonstrated considerable volatility. It decreased from 6.60 in July 2020 to a low of 3.68 in January 2021, before recovering significantly to a peak of 11.08 in July 2022. The ratio then decreased to 8.81 in July 2025. While remaining above 7.72 throughout the period, the declining trend in recent quarters warrants monitoring, as it indicates a potentially weakening ability to meet interest obligations from earnings.
In summary, the company’s solvency ratios suggest a generally stable financial structure with a recent trend towards increased leverage. While the interest coverage ratio remains healthy, its recent decline should be observed for potential implications on the company’s ability to service its debt.
Debt Ratios
Coverage Ratios
Debt to Equity
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current debt obligations | ||||||||||||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to equity1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio for the observed period demonstrates a generally stable trend with some fluctuation. Initially, the ratio increased from 0.57 to 0.60 between July 2020 and January 2021, indicating a relative increase in debt compared to equity. A subsequent decrease was then observed, falling to a low of 0.44 by April 2022. The ratio experienced an increase again, peaking at 0.60 in January 2025, before decreasing slightly to 0.57 in the final observed period.
- Overall Trend
- The ratio generally fluctuated between 0.44 and 0.60 throughout the period. While there were periods of increase and decrease, the ratio remained within a relatively constrained range, suggesting a consistent approach to capital structure. The most significant increase occurred between April 2024 and January 2025.
- Initial Phase (July 2020 – April 2021)
- The initial period showed a slight increase in the debt to equity ratio, moving from 0.57 to 0.60. This suggests a potential increase in leverage during this time, though the change was moderate.
- Decreasing Phase (April 2021 – April 2022)
- A notable downward trend was observed from April 2021 to April 2022, with the ratio decreasing from 0.51 to 0.44. This indicates a reduction in leverage, potentially through debt repayment or an increase in shareholder equity.
- Fluctuating Phase (April 2022 – January 2025)
- Following the decrease, the ratio experienced fluctuations, moving between 0.46 and 0.60. This period suggests a more dynamic approach to capital structure management, with adjustments made to the debt and equity mix. The increase to 0.60 in January 2025 is the highest point in the observed period.
- Final Phase (January 2025 – January 2026)
- The final observed period shows a slight decrease from 0.60 to 0.57, indicating a minor reduction in leverage. This suggests a potential recalibration of the capital structure towards the end of the period.
In summary, the debt to equity ratio demonstrates a pattern of moderate fluctuation, with periods of increasing and decreasing leverage. The ratio remained within a defined range, suggesting a generally stable capital structure, although the increase in the ratio towards the end of the period warrants further investigation.
Debt to Capital
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current debt obligations | ||||||||||||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||||||||||||
| Total capital | ||||||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to capital1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a generally stable trend with some fluctuations. Initially, the ratio exhibits a slight increase before stabilizing and then experiencing a modest rise towards the end of the observed timeframe.
- Initial Trend (Jul 31, 2020 – Jan 28, 2022)
- The debt to capital ratio began at 0.36 and increased to 0.37 by October 30, 2020, remaining at that level through January 29, 2021. A slight decrease was then observed, falling to 0.32 by January 28, 2022. This initial period suggests a modest increase in leverage followed by a slight deleveraging.
- Stabilization and Fluctuation (Apr 29, 2022 – Oct 27, 2023)
- From April 29, 2022, to October 27, 2023, the ratio fluctuated between 0.31 and 0.35. This indicates a period of relative stability in the company’s capital structure, with no significant directional movement. The ratio briefly rose to 0.34 in October 28, 2022, and remained around 0.33 for the subsequent three quarters.
- Recent Trend (Jan 26, 2024 – Oct 24, 2025)
- Beginning in January 2024, the ratio experienced an increase, reaching 0.37 by July 26, 2024, and remaining at that level through October 25, 2024. It then decreased slightly to 0.35 in January 24, 2025, before rising again to 0.37 by October 24, 2025. This recent trend suggests a potential increase in the company’s reliance on debt financing.
- Overall Assessment
- Throughout the analyzed period, the debt to capital ratio remained within a relatively narrow range, generally between 0.32 and 0.37. While fluctuations occurred, there were no dramatic shifts, indicating a consistent approach to capital structure management. The recent increase warrants monitoring to assess whether it represents a strategic shift or a temporary deviation.
In summary, the company’s debt to capital ratio has demonstrated a pattern of initial slight increase, stabilization, and a more recent modest rise. The overall trend suggests a generally conservative capital structure, though the latest figures indicate a potential shift towards increased leverage.
Debt to Assets
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current debt obligations | ||||||||||||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to assets1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio for the analyzed period demonstrates a generally stable pattern with minor fluctuations. Initially, the ratio remained consistent at 0.31 for the first three periods observed. A slight decrease was then noted, falling to 0.28 for two consecutive periods before stabilizing around 0.27 to 0.28 for the subsequent six periods.
A modest increase in the ratio is observed starting in the tenth period, rising to 0.29 and then 0.30. This upward trend continues, reaching 0.31 and peaking at 0.32 in the twenty-fourth period. The final period shows a slight decrease to 0.31.
- Overall Trend
- The overall trend indicates a relatively low and stable level of debt relative to assets. While fluctuations occur, the ratio generally remains within a narrow band between 0.26 and 0.32. The recent increase towards the end of the analyzed period warrants monitoring, though it remains within a reasonable range.
- Short-Term Fluctuations
- Short-term fluctuations appear to be influenced by changes in both total debt and total assets. The initial decrease from 0.31 to 0.28 coincides with a reduction in total debt, while the subsequent increases are linked to either increases in debt or decreases in assets, or a combination of both.
- Recent Developments
- The most recent periods show a slight increase in the debt-to-assets ratio, moving from 0.28 to 0.31 over four periods. This suggests a potential shift in the company’s capital structure, possibly indicating increased reliance on debt financing or a decrease in asset value. Further investigation into the underlying drivers of these changes is recommended.
In summary, the debt-to-assets ratio suggests a conservative financial leverage position throughout most of the analyzed period. The recent increase, while not substantial, should be monitored to assess its potential implications for the company’s long-term solvency.
Financial Leverage
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Financial leverage1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial leverage ratio for the observed period demonstrates a generally stable pattern with some fluctuation. Initially, the ratio exhibits a slight increasing trend, followed by a period of relative stability, and then a modest increase towards the end of the analyzed timeframe.
- Overall Trend
- The financial leverage ratio begins at 1.87 and generally fluctuates between 1.71 and 1.92 throughout the period. The latter portion of the timeframe shows a slight upward trend, closing at 1.87.
- Initial Phase (Jul 31, 2020 – Jan 28, 2022)
- From July 31, 2020, to January 28, 2022, the ratio increased from 1.87 to 1.92, peaking at 1.92 in January 2021. This suggests a gradual increase in the proportion of assets financed by debt during this period. However, the ratio then decreased to 1.75 by January 2022, indicating a slight reduction in financial leverage.
- Stabilization and Subsequent Increase (Apr 29, 2022 – Oct 24, 2025)
- Following January 2022, the ratio remained relatively stable, fluctuating between 1.73 and 1.83 for several quarters. A noticeable increase begins in July 2024, rising from 1.79 to 1.91 by April 2025. This indicates a renewed reliance on debt financing. The ratio then slightly decreases to 1.87 by October 2025.
- Shareholders’ Equity and Total Assets
- Total assets experienced a moderate decline from 93,906 to 90,087 between July 2020 and October 2022, before increasing to 93,241 by October 2022. Shareholders’ equity generally increased from 50,296 to 52,672 by October 2022, but then decreased to 47,893 by July 2025, before recovering to 48,985 by October 2025. These movements in the denominator and numerator of the leverage ratio contribute to the observed fluctuations.
The observed fluctuations in financial leverage suggest a dynamic capital structure management strategy. While the company generally maintains a consistent level of leverage, the periodic increases and decreases warrant further investigation to understand the underlying drivers, such as debt issuance, repayment, and equity changes.
Interest Coverage
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net income attributable to Medtronic | ||||||||||||||||||||||||||||||
| Add: Net income attributable to noncontrolling interest | ||||||||||||||||||||||||||||||
| Add: Income tax expense | ||||||||||||||||||||||||||||||
| Add: Interest expense, net | ||||||||||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | ||||||||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Interest coverage1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Interest coverage
= (EBITQ3 2026
+ EBITQ2 2026
+ EBITQ1 2026
+ EBITQ4 2025)
÷ (Interest expenseQ3 2026
+ Interest expenseQ2 2026
+ Interest expenseQ1 2026
+ Interest expenseQ4 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio for the analyzed period demonstrates considerable fluctuation, though generally remains above a level indicative of comfortable debt servicing capacity. Initial values show a decline followed by a period of relative stability and then a recent downward trend. A detailed examination of the ratio’s behavior over the observed timeframe reveals several distinct phases.
- Initial Decline and Recovery (Jul 31, 2020 – Apr 30, 2021)
- The interest coverage ratio began at 6.60 and experienced a notable decrease to 3.68 by January 29, 2021. This decline suggests a weakening ability to meet interest obligations from operating earnings during this period. However, a subsequent recovery was observed, with the ratio increasing to 5.21 by April 30, 2021, indicating improved earnings relative to interest expense.
- Period of Strength (Jul 30, 2021 – Apr 29, 2022)
- From July 30, 2021, through April 29, 2022, the interest coverage ratio exhibited a period of strength, consistently exceeding 10.00. The peak value of 10.98 was recorded on April 29, 2022. This suggests a robust capacity to cover interest expenses with earnings before interest and taxes during this timeframe. The ratio remained relatively stable within this range.
- Recent Downward Trend (Jul 29, 2022 – Apr 26, 2024)
- Beginning in July 2022, a gradual downward trend in the interest coverage ratio became apparent. While remaining above 7.00 for most of this period, the ratio decreased from 10.88 to 7.73 by April 26, 2024. This suggests a gradual erosion of the cushion available to cover interest payments, potentially due to increasing interest expense or slower growth in EBIT.
- Stabilization and Slight Increase (Jul 26, 2024 – Apr 25, 2025)
- The most recent observations indicate a slight stabilization, with the ratio fluctuating between 7.65 and 8.72. The ratio reached 8.72 in April 2025. This suggests that the downward trend may be moderating, but continued monitoring is warranted.
Overall, the interest coverage ratio demonstrates a cyclical pattern. While historically strong, the recent decline warrants attention. The company maintains a generally healthy interest coverage ratio, but the trend suggests a potential need to monitor earnings and debt levels closely to ensure continued solvency.